Of the 30 patients (mean age of 53 ± 12 years) with metastatic ER+/HER2- BC included in the study and treated with CDK 4/6 inhibitors, 19 patients (63.3%) were in menopause while 11 (36.7%) were not. Here, ERBB2 is linked to breast cancer.